Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 study of NBI-921352 adjunctive therapy in SCN8A developmental and epileptic encephalopathy
2020-003140-83Phase 2Completed
- Sponsor
- Neurocrine Biosciences
- Start
- Sep 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in developmental and epileptic encephalopathy 13 (DEE13) and epileptic encephalopathy comparing NBI-921352 adjunctive therapy with Placebo adjunctive therapy (2 arms). Primary endpoint: Percentage change from baseline in 28-day seizure frequency for countable motor seizures during the treatment period. Started Sep 2021; status: completed.
02
Drugs
zandatrigine
03
Conditions
developmental and epileptic encephalopathy 13 (DEE13)epileptic encephalopathy
Beyond the preview
Go deeper on 2020-003140-83.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-003140-83.